Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Objective: To determine the effect of the introduction of low dose computed tomography screening in 2013 on lung cancer stage shift, survival, and disparities in the stage of lung cancer diagnosed in the United States. Design: Quasi-experimental study using Joinpoint modeling, multivariable ordinal logistic regression, and multivariable Cox proportional hazards modeling. Setting: US National Cancer Database and Surveillance Epidemiology End Results program database. Participants: Patients aged 45-80 years diagnosed as having non-small cell lung cancer (NSCLC) between 1 January 2010 and 31 December 2018. Main outcome measures: Annual per cent change in percentage of stage I NSCLC diagnosed among patients aged 45-54 (ineligible for screening) and 55-80 (potentially eligible for screening), median all cause survival, and incidence of NSCLC; multivariable adjusted odds ratios for year-to-year changes in likelihood of having earlier stages of disease at diagnosis and multivariable adjusted hazard ratios for changes in hazard of death before versus after introduction of screening. Results: The percentage of stage I NSCLC diagnosed among patients aged 55-80 did not significantly increase from 2010 to 2013 (from 27.8% to 29.4%) and then increased at 3.9% (95% confidence interval 3.0% to 4.8%) per year from 2014 to 2018 (from 30.2% to 35.5%). In multivariable adjusted analysis, the increase in the odds per year of a patient having one lung cancer stage lower at diagnosis during the time period from 2014 to 2018 was 6.2% (multivariable adjusted odds ratio 1.062, 95% confidence interval 1.048 to 1.077; P<0.001) higher than the increase in the odds per year from 2010 to 2013. Similarly, the median all cause survival of patients aged 55-80 did not significantly increase from 2010 to 2013 (from 15.8 to 18.1 months), and then increased at 11.9% (8.9% to 15.0%) per year from 2014 to 2018 (from 19.7 to 28.2 months). In multivariable adjusted analysis, the hazard of death decreased significantly faster after 2014 compared with before 2014 (P<0.001). By 2018, stage I NSCLC was the predominant diagnosis among non-Hispanic white people and people living in the highest income or best educated regions. Non-white people and those living in lower income or less educated regions remained more likely to have stage IV disease at diagnosis. Increases in the detection of early stage disease in the US from 2014 to 2018 led to an estimated 10 100 averted deaths. Conclusions: A recent stage shift toward stage I NSCLC coincides with improved survival and the introduction of lung cancer screening. Non-white patients and those living in areas of greater deprivation had lower rates of stage I disease identified, highlighting the need for efforts to increase access to screening in the US.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial
de Koning, H. J., van der Aalst, C. M., de Jong, P. A., Scholten, E. T., Nackaerts, K., Heuvelmans, M. A., Lammers, J.-W. J., Weenink, C., Yousaf-Khan, U., Horeweg, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911793 · Cited by 3,624
Tobacco product use among adults—United States, 2019.
Cornelius, M. E., Wang, T. W., Jamal, A., Loretan, C. G., & Neff, L. J. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6946a4 · Cited by 975
Rural areas at risk during COVID-19 pandemic
Ranscombe, P. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30301-7 · Cited by 167
Cited by
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21820 · Cited by 9,533
“5 Progress not only reflects improved disease management 84 ‐ 86 but also earlier detection 87,88 and advances in staging.”
BackgroundSiegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H., & Jemal, A. (2025) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21871 · Cited by 3,060
Adams, S. J., Stone, E., Baldwin, D. R., Vliegenthart, R., Lee, P., & Fintelmann, F. J. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01694-4 · Cited by 467
Self-citationAguiar-Ibáñez, R., Mbous, Y. P. V., Sharma, S., & Chawla, E. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1546447 · Cited by 17
Metadata
- Authors
- Potter, A. L., Rosenstein, A. L., Kiang, M. V., Shah, S. A., Gaissert, H. A., Chang, D. C., Fintelmann, F. J., & Yang, C.-F. J.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2022-03-30
- Volume
- 376
- Pages
- e069008
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W4220808004
- Cited by
- 127
- References
- 5
- FWCI
- 15.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study. https://app.cochat.ai/papers/10.1136/bmj-2021-069008
- The paper
- Potter, A. L., Rosenstein, A. L., Kiang, M. V., Shah, S. A., Gaissert, H. A., Chang, D. C., Fintelmann, F. J., & Yang, C.-F. J. (2022). Association of computed tomography screening with lung cancer stage shift and survival in the United States: quasi-experimental study. BMJ. https://doi.org/10.1136/bmj-2021-069008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.